<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023540</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-PXT3003-03</org_study_id>
    <secondary_id>2015-002379-81</secondary_id>
    <nct_id>NCT03023540</nct_id>
  </id_info>
  <brief_title>Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A</brief_title>
  <acronym>PLEO-CMT-FU</acronym>
  <official_title>International, Multi-center, Open Label, 9-month Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharnext SA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SynteractHCR</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharnext SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All randomised patients with Charcot-Marie-Tooth Type 1A (CMT1A) who completed the primary
      study CLN-PXT3003-02, i.e. treatment with PXT3003 or placebo, will be eligible to continue in
      the extension study CLN-PXT3003-03.

      Patients randomised to PXT3003 dose 1 or placebo in the primary study (CLN-PXT3003-02) will
      continue in the extension study on PXT3003 dose 1 (5 mL). Patients randomised to PXT3003 dose
      2 (5 mL) in the primary study (CLN-PXT3003-02) will continue in the extension study on
      PXT3003 twice dose 1 (2x5 mL).

      Patients previously randomised to PXT3003 dose 1 (5 mL) in the extension study
      (CLN-PXT3003-03) before September 18th 2017 will continue on dose 1 (5 mL). Patients
      previously randomised to PXT3003 dose 2 (5 mL) in the extension study (CLN-PXT3003-03) before
      September 18th 2017 will continue on PXT3003 twice dose 1 (2x5 mL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PXT3003 is a rational design, fixed combination of low-dose (RS) baclofen, naltrexone
      hydrochloride and D-sorbitol. The use of PXT3003 in a multicenter, randomised, placebo
      controlled phase II study (CLN-PXT3003-01) was well-tolerated and safe in patients with CMT1A
      for the three dose-levels investigated (Attarian et al., 2014). The intermediate and high
      dose of PXT3003 demonstrated an improvement of disability in this patient population.

      Subsequently a multicenter, randomised, placebo controlled phase III study (CLN-PXT3003-02)
      to assess the efficacy and safety of PXT3003 in the treatment of patients with CMT1A was
      initiated in December 2015. In March 2017 the first patients will have completed the 15-month
      treatment with PXT3003. September 18th 2017, the PXT3003 dose 2 was prematurely discontinued
      by the Sponsor. Thereafter, patients will be allowed for entry in this extension study
      (CLN-PXT3003-03) for a 9-month treatment with PXT3003. Thus patients initially randomised to
      active treatment will have used PXT3003 for up to 24 months, whereas patients initially
      randomized to inactive treatment will have used PXT3003 for up to 9 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) related to PXT3003 during the follow-up in patients with CMT1A</measure>
    <time_frame>9 or 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of all TEAEs and their evaluation of type/nature, severity/intensity, seriousness, duration, relationship to study drug, and outcome</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events leading to withdrawal of study drug</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Neuropathy Limitation Scale (ONLS) score, and its arm and leg sub-items</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Charcot-Marie-Tooth Neuropathy Score - version 2 (CMTNS-V2), and its sub-items</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nine-hole Peg Test (9-HPT)</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantified Muscular Testing (QMT) by hand grip and foot dorsiflexion dynamometry (mean of both sides)</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to walk 10 meters</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compound Muscle Action Potential (CMAP) on ulnar nerve</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory Nerve Action Potential (SNAP) on radial nerve</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nerve conduction velocity (NCV)</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>9 or 24 months</time_frame>
    <description>EuroQol 5-Dimensional Health-related Quality of Life scale (EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale on self-assessment of individualized main impairment in daily activities (defined at baseline with the patient)</measure>
    <time_frame>9 or 24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Through plasma concentration of PXT3003</measure>
    <time_frame>at month 6 and 9</time_frame>
    <description>Measurement of baclofen, naltrexone and 6-beta-naltrexone plasma concentration at the through</description>
  </other_outcome>
  <other_outcome>
    <measure>Peak plasma concentration of PXT3003</measure>
    <time_frame>at month 6 and 9</time_frame>
    <description>Measurement of baclofen, naltrexone and 6-beta-naltrexone plasma concentration at the through</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">323</enrollment>
  <condition>Charcot-Marie-Tooth Disease, Type IA</condition>
  <arm_group>
    <arm_group_label>PXT3003 dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PXT3003: Liquid oral solution, 5 mL bid (taken morning and evening with food) for 9 consecutive months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXT3003 dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PXT3003: Liquid oral solution, 5 mL bid (taken morning and evening with food) for 9 consecutive months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT3003</intervention_name>
    <description>Liquid oral solution, 5 mL bid for 9 consecutive months</description>
    <arm_group_label>PXT3003 dose 1</arm_group_label>
    <arm_group_label>PXT3003 dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria after September 18th 2017:

          -  Patients previously randomized to study CLN-PXT3003-02 under placebo and dose 1 and
             having completed 15 months of double-blind treatment in that study, including all
             procedures required at the Study Termination visit (V6) or

          -  Patients previously randomized to the initial study CLN-PXT3003-02 under dose 2,
             prematurely discontinued following sponsor decision, and having performed all
             procedures required at the Study Termination visit (V6)

          -  Patients whose V6 was performed within 4 weeks before entering the extension study or
             if not done must have a new baseline visit (VB)

          -  Female patients must agree to continue using an approved method of birth control
             throughout the extension study

          -  Patients must sign a written informed consent, specific to the extension study, in
             order to participate in this study. In case of minor children aged 16 to 18 years,
             both parent' and children's consents should be collected

        Inclusion Criteria until September 18th 2017:

          -  Patients must have completed 15 months of double-blind treatment in the primary study
             CLN-PXT3003-02, including all procedures required at the Study Termination visit (V6)

          -  Female patients must agree to continue using an approved method of birth control
             throughout the extension study

          -  Patients must sign a written informed consent, specific to the extension study, in
             order to participate in this study. In case of minor children aged 16 to 18 years,
             both parent' and children's consents should be collected

        Exclusion Criteria:

          -  Any clinically significant change in health status that, in the opinion of the
             Investigator, would prevent the subject from participating in this study or
             successfully completing this study

          -  Any unauthorized concomitant treatments, as study CLN-PXT3003-02 (e.g. including but
             not limited to baclofen, naltrexone,sorbitol (pharmaceutical form), opioids,
             levothyroxin, and potentially neurotoxic drugs such as amiodarone, chloroquine, cancer
             drugs susceptible to induce peripheral neuropathy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahram Attarian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU la Timone, Marseille, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Munster, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Sevilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario i Politécnico La F, Valencia, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne de Visser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center, Amsterdam, Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Roberts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Selor Royal NHS Foundation Trust, Manchester, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florian Thomas, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seton Hall-Hackensack-Meridian School of Medicine, Hackensack, USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rene Goedkoop, MD</last_name>
    <phone>+33 1 41 09 22 30</phone>
    <email>rgoedkoop@pharnext.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Cohen, MD PhD</last_name>
    <phone>+33 1 41 09 22 30</phone>
    <email>dcohen@pharnext.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, McKnight Brain Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Statland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony A Amato, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Department of Neurology and Psichiatry, Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104-1027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Peripheral Neuropathy Center, Neurological Institue Building, Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Rehabilitation Institute</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202-1330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Departement of Neurology, UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jack Puymirat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cntre de Reference des Maladies Neuromusculaires, Hopital Swynghedauwl, CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre de Reference des Neuropathies Peripheriques Rare, Hopital Dupuytren, CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie et du Sommeil, CHU Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre de Reference des Maladie Neuromusculaires, CHU la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre de Reference des Maladie Neuromusculaires, Hotel Dieu, CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie, Hopital Kremlin Bicetre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Adams, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology and Institute for Neuropathology, University Hospital RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Burkhard Gess, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Neurophysiology, University Medical Center Göttingen</name>
      <address>
        <city>Gottingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Czesnik, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Ludwig-Maximillian University, Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maggie Walter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department for Sleep Medicine and Neuromuscular disease, University Hospital Münster</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Young, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Departement of Neurology, Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Department of neurology, Hospital Univesitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Casasnovas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurologia, Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centro de Diagnostico y Tratamiento, Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celedonio Marquez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurologia, Hospital Universitario i Politécnic La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Charcot Marie Tooth Type 1A</keyword>
  <keyword>Peripheral neuropathy</keyword>
  <keyword>PXT3003</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

